In This Article:
Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the Board
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 22, 2025) - BioHarvest Sciences Inc., (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today announced that Mr. Sharon Malka has agreed to serve as an independent director of BioHarvest. The appointment is effective immediately.
"We are very pleased to announce the addition of Mr. Malka to the BioHarvest Board of Directors," said Dr. Zaki Rakib, Chairman of the Board and President of BioHarvest Sciences' CDMO Services Division. "His operational experience in advancing innovative technologies, and in structuring strategic transactions and major financing rounds, will be invaluable to BioHarvest in our current and future growth stages."
Sharon Malka
To view an enhanced version of this graphic, please visit:
https:/https://finance.yahoo.com/images.newsfilecorp.com/files/6168/238061_a1207bd8b47a5ab9_001full.jpg
Sharon Malka, stated: "I am delighted to join BioHarvest as an independent director and am impressed with the Company's commitment to develop the next generation of science-based and clinically proven therapeutic solutions. With its leading-edge Botanical Synthesis technology, BioHarvest is poised for significant growth, and I am keen to contribute my experience and knowledge to support BioHarvest in its future success."
"Sharon is a veteran capital markets and technology executive, whose perspective and experience will be very valuable as we scale our Botanical Synthesis technology and expand our operations," commented CEO Ilan Sobel. "We are very pleased to have Sharon join our Board during this transformative phase of the company's growth."
Mr. Sharon Malka Detailed Biography
Sharon Malka brings a wealth of experience to BioHarvest, having held senior leadership positions with a number of international healthcare and technology companies. He is currently Chief Executive Officer of Dotz Nano Ltd., an Australian-based technology company focused on developing, manufacturing and commercializing advanced materials for diagnostics solutions. Mr. Sharon is currently on the Board of Directors of MediWound Limited, a Nasdaq-listed biopharmaceutical company, where he also previously served as both Chief Financial Officer and Chief Executive Officer. Prior to Mediwound, Sharon held the role of Partner at Variance Economic Consulting Ltd., a financial services consulting boutique focused on international technology company.